Magnesium Citrate

Description

CVS Citrate Cherry 5-23 is a pharmaceutical formulation designed for specific therapeutic applications. The product is presented in a liquid dosage form, characterized by its cherry flavor. The formulation contains citrate as a key active ingredient, contributing to its intended pharmacological effects. The precise molecular weight and chemical composition are integral to its efficacy and safety profile. The product is intended for use under professional guidance, ensuring appropriate dosing and administration in accordance with established medical protocols.

Uses and Indications

This drug is indicated for the relief of occasional constipation (irregularity). It generally produces a bowel movement within 1/2 to 6 hours of administration.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The medication should be shaken well before use. It is recommended that patients drink a full glass (8 ounces) of liquid with each dose. The medication may be administered as a single daily dose or divided into multiple doses throughout the day.

For adults and children aged 12 years and older, the dosage ranges from 6.5 to 10 fluid ounces, with a maximum limit of 10 fluid ounces within a 24-hour period. For children aged 6 to under 12 years, the recommended dosage is between 3 to 7 fluid ounces, not exceeding 7 fluid ounces in a 24-hour period. For children aged 2 to under 6 years, the dosage should be between 2 to 3 fluid ounces, with a maximum of 3 fluid ounces in a 24-hour period. For children under 2 years of age, it is advised to consult a physician for appropriate dosing recommendations.

Contraindications

Use of this product is contraindicated in patients experiencing rectal bleeding or failure to have a bowel movement after use, as these may indicate a serious underlying condition requiring medical evaluation.

Additionally, caution is advised for patients taking other medications; it is recommended to consult a healthcare professional prior to use. This product should be administered at least 2 hours before or after other drugs, as laxatives may alter the efficacy of concurrent medications.

Warnings and Precautions

Patients with a history of kidney disease should exercise caution when using this medication, as it may exacerbate their condition. Additionally, individuals on a magnesium-restricted diet must be aware of the potential for increased magnesium levels, which could lead to serious complications.

Healthcare professionals should monitor patients for gastrointestinal symptoms such as abdominal pain, nausea, or vomiting. If patients experience a sudden change in bowel habits that persists for more than two weeks, they should be advised to seek medical evaluation. Furthermore, if a laxative has been used for longer than one week, it is essential to reassess the treatment plan to avoid potential complications.

Patients are instructed to discontinue use and contact their healthcare provider immediately if they experience rectal bleeding or fail to have a bowel movement after using the medication, as these symptoms may indicate a serious underlying condition.

In the event of an overdose, it is critical to seek emergency medical assistance or contact a Poison Control Center without delay to ensure appropriate management and care.

Side Effects

Patients may experience a range of adverse reactions associated with the use of this product. Serious adverse reactions include rectal bleeding and failure to have a bowel movement after use, which may indicate a serious underlying condition. Patients are advised to discontinue use and consult a healthcare professional if they experience these symptoms.

Common adverse reactions may include abdominal pain, nausea, or vomiting. Additionally, patients with pre-existing kidney disease or those on a magnesium-restricted diet should exercise caution when using this product. A sudden change in bowel habits that persists for more than two weeks or the prolonged use of a laxative for more than one week are also warnings that necessitate medical consultation.

It is important for patients to inform their healthcare provider or pharmacist if they are taking any other medications, as laxatives may influence the efficacy of concurrent drug therapies.

Drug Interactions

Patients are advised to consult a healthcare professional, such as a doctor or pharmacist, prior to using this product if they are currently taking any other medications.

It is recommended that this product be administered at least 2 hours before or after the administration of other drugs. This precaution is particularly important as laxatives may influence the efficacy of concurrent medications. Monitoring for potential interactions is advised to ensure optimal therapeutic outcomes.

Packaging & NDC

Below are the non-prescription pack sizes of Magnesium Citrate (cvs magnesium citrate oral solution - cherry). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may receive a maximum dosage of 3 to 7 fluid ounces within a 24-hour period, with a strict limit of 7 fluid ounces. For children aged 2 to under 6 years, the recommended dosage is 2 to 3 fluid ounces in a 24-hour period, not exceeding 3 fluid ounces. For infants under 2 years of age, it is advised to consult a doctor before administration.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to discuss their individual circumstances with their healthcare provider to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a healthcare professional prior to using this medication. There is no specific data available regarding the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment may require careful consideration regarding dosing adjustments and monitoring. In individuals with reduced kidney function, particularly those with kidney disease, it is essential to assess renal clearance to ensure appropriate therapeutic levels are maintained. Additionally, patients may need to adhere to a magnesium-restricted diet to prevent potential complications associated with elevated magnesium levels. Regular monitoring of renal function is recommended to guide treatment decisions and adjust dosages as necessary.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data regarding its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

In the event of an overdosage, it is important to note that there is no specific information regarding overdosage provided in the available sections of the drug insert.

Healthcare professionals are advised to monitor the patient closely for any potential symptoms that may arise, although specific symptoms related to overdosage have not been detailed.

In the absence of defined overdosage management protocols, standard supportive care should be implemented. This may include symptomatic treatment and monitoring of vital signs. If necessary, healthcare providers should consider consulting a poison control center for further guidance on management strategies tailored to the individual patient's needs.

As always, it is crucial to report any adverse events or unexpected reactions to the appropriate regulatory authorities to enhance the understanding of the drug's safety profile.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center in the event of an overdose. It is crucial for patients to understand the importance of stopping the use of this product and consulting a doctor if they experience rectal bleeding or fail to have a bowel movement after use, as these symptoms may indicate a serious underlying condition.

Patients should also be encouraged to consult with their healthcare provider or pharmacist prior to using this product if they are currently taking any other medications. It is important to inform patients that they should take this product at least 2 hours before or after taking other drugs, as laxatives may influence the effectiveness of concurrent medications.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at temperatures ranging from 46° to 86°F (8° to 30°C) to maintain its efficacy and safety. Proper container requirements must be adhered to, ensuring that the product is kept in an appropriate environment. Special handling needs should be observed to prevent any compromise to the product's integrity.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Magnesium Citrate, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)